Transplantation Reviews最新文献

{"title":"Harnessing the TNF-TNFR pathway for graft tolerance: Selective immunomodulation in islet transplantation","authors":"Qibin Wu ,&nbsp;Yinglin Yuan ,&nbsp;Hongji Yang ,&nbsp;Qiang Fu","doi":"10.1016/j.trre.2025.100962","DOIUrl":"10.1016/j.trre.2025.100962","url":null,"abstract":"<div><div>Islet transplantation represents a promising treatment for patients with insulin-dependent diabetes or unstable glycemic control. However, its widespread application faces two major challenges: a severe shortage of donor organs and persistent immune rejection. Recent studies consistently indicate that broad blockade of the TNFR signaling pathway is insufficient for controlling autoimmune inflammation. Instead, selectively attenuating the pro-inflammatory TNFR1 pathway while enhancing the anti-inflammatory TNFR2 pathway may offer a more effective strategy. This review is the first to explore, from an islet transplantation perspective, the potential of selective TNFR pathway targeting to promote graft tolerance. We specifically highlight the emerging role of regulatory B cells (Bregs) as key mediators in this process, and propose that targeted enhancement of their immunosuppressive function—particularly through the TNF-TNFR2 signaling axis—represents a promising therapeutic strategy to promote the induction of regulatory T cells (Tregs) and achieve durable transplant tolerance.</div></div>","PeriodicalId":48973,"journal":{"name":"Transplantation Reviews","volume":"39 4","pages":"Article 100962"},"PeriodicalIF":3.6,"publicationDate":"2025-09-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145060255","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of donor-recipient size mismatch on post-transplant outcomes in kidney transplant recipients: A systematic review","authors":"Sabaa Asif ,&nbsp;Christie Rampersad ,&nbsp;Ani Orchanian-Cheff ,&nbsp;S. Joseph Kim","doi":"10.1016/j.trre.2025.100965","DOIUrl":"10.1016/j.trre.2025.100965","url":null,"abstract":"<div><h3>Background</h3><div>Donor-recipient size mismatch builds on the nephron dosing concept, but studies suggest unclear associations with kidney allograft outcomes.</div></div><div><h3>Methods</h3><div>We systematically searched, critically appraised, and summarized associations between donor-recipient size mismatch and primary outcome of death-censored graft failure, secondary outcomes of kidney function, all-cause graft failure, and mortality. The study protocol was registered a priori on PROSPERO (ID CRD42023455394). We searched MEDLINE, Embase, and Cochrane Databases from 1946 to 2025 for studies evaluating adult kidney transplant recipients. We excluded non-English or unavailable full texts, and studies with donors &lt;16 years old. Risk of bias was assessed using Risk of Bias in Non-randomized Studies – of Exposure tool. Studies were narratively synthesized; marked heterogeneity precluded quantitative meta-analysis.</div></div><div><h3>Results</h3><div>From 1521 citations, 56 studies were included. Sample sizes ranged from 23 to 238,895 donor-recipient pairs (median 214, IQR [95, 807]), with follow-up from 1 week to &gt;20 years. Studies varied in size mismatch definitions, exposure subgrouping, outcomes, patient populations, and follow-up period. Overall, 32 % demonstrated worse kidney allograft outcomes with unfavorable size mismatch, 9 % showed no association, and 59 % reported mixed findings. All studies had high or very high risk of bias.</div></div><div><h3>Conclusions</h3><div>Available studies do not provide strong evidence to support or reject the idea of nephron underdosing, however existing reports were generally of poor quality, with high or very high risk of bias. Due to data heterogeneity, quantitative meta-analysis was not performed. Well-designed studies with clear exposure definitions, standardized outcome assessments, appropriate confounder control, adequate follow-up, and robust statistical analyses remain a priority.</div></div>","PeriodicalId":48973,"journal":{"name":"Transplantation Reviews","volume":"39 4","pages":"Article 100965"},"PeriodicalIF":3.6,"publicationDate":"2025-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145048596","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Early surgical complications following kidney transplantation in adults: A systematic review","authors":"Milla Ortved ,&nbsp;Julia Dagnæs-Hansen ,&nbsp;Hein V. Stroomberg ,&nbsp;Malene Rohrsted ,&nbsp;Søren Schwartz Sørensen ,&nbsp;Andreas Røder","doi":"10.1016/j.trre.2025.100963","DOIUrl":"10.1016/j.trre.2025.100963","url":null,"abstract":"<div><h3>Objective</h3><div>To quantify and characterise short-term (&lt;90 days) surgical complications following kidney transplantation and identify risk factors for complications.</div></div><div><h3>Methods</h3><div>This systematic review was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines and the protocol registered with PROSPERO (ID CRD42024535328). Studies reporting surgical and postoperative complications within 90 days of surgery were included as well as studies reporting on groups of complications such as urological, vascular or wound related. The quality of evidence was assessed using the Newcastle-Ottawa Scale (NOS) and number of fulfilled Martin criteria.</div></div><div><h3>Results</h3><div>Of 1654 articles screened, 30 were included. In studies reporting on complications within 30 days of surgery the weighted overall complication rate was 41 % (range 13-70 %), the weighted reoperation rate was 13 % (range 9.8-17 %) and the weighted rate of major complications was 19 % (range 7.6-24 %). In studies reporting on complications within 90 days of surgery the weighted overall complication rate was 36 % (range 12-60 %), the weighted reoperation rate was 17 % (range 5.0-23 %) and the weighted rate of major complications was 24 % (range 19-25 %). Studies were heterogenous and the quality was rated poor to good according to the NOS and fulfilling a median of 7 Martin criteria (range 4-9). Possible risk factors for complications included high BMI, recipient age and sex.</div></div><div><h3>Conclusion</h3><div>Kidney transplantation remains a high-risk surgical procedure. We identified considerable variation in how complications were reported, limiting comparison of outcomes between centres as well as the potential impact of peri-operative interventions to improve surgical outcomes.</div></div>","PeriodicalId":48973,"journal":{"name":"Transplantation Reviews","volume":"39 4","pages":"Article 100963"},"PeriodicalIF":3.6,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144996571","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of disease-modifying drugs in patients with transthyretin amyloidosis after liver transplantation: a systematic review","authors":"Christiane Santo,&nbsp;Cristhian Romero,&nbsp;Bruno Vaz Kerges Bueno,&nbsp;Andre Dabarian,&nbsp;Fabio Fernandes","doi":"10.1016/j.trre.2025.100960","DOIUrl":"10.1016/j.trre.2025.100960","url":null,"abstract":"<div><h3>Background</h3><div>Orthotopic liver transplant (OLT) was the first approved treatment for hereditary transthyretin amyloidosis (ATTRv). However, some patients continue to deteriorate due to ongoing wild-type TTR deposition and residual synthesis from extrahepatic sources. In recent years, disease-modifying therapies including TTR stabilizers (e.g., Tafamidis) and gene-silencing agents (e.g., Patisiran) have emerged, but their role in post-OLT patients remains unclear due to their exclusion from most clinical trials.</div></div><div><h3>Methods</h3><div>A systematic search was conducted in PubMed, Cochrane, and Embase (up to June 2025) using terms related to transthyretin amyloidosis, liver transplantation, and disease-modifying therapies. The objective was to evaluate clinical benefits and safety of these agents in symptomatic ATTRv patients after OLT.</div></div><div><h3>Results</h3><div>Disease-modifying therapies showed potential benefits in post-OLT ATTR patients. A total of 39 patients treated with tafamidis, inotersen, or patisiran were analyzed. Neurological improvements, including autonomic symptoms, NIS score, and quality of life, were based on 3 case reports and 32 patients from observational studies. Cardiovascular results were from 4 case reports, and biomarker findings from 3 case reports.</div></div><div><h3>Conclusions</h3><div>Disease-modifying therapies may offer clinical benefits in post-OLT ATTRv patients. However, robust prospective studies and randomized trials are needed to confirm efficacy and ensure safety in this population.</div></div>","PeriodicalId":48973,"journal":{"name":"Transplantation Reviews","volume":"39 4","pages":"Article 100960"},"PeriodicalIF":3.6,"publicationDate":"2025-08-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144903285","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Between uncertainty and hope: A meta-ethnographic synthesis of patients awaiting kidney transplantation","authors":"Ebru Akgün Çıtak,&nbsp;Tuğçe Uçgun,&nbsp;Aylin Günay,&nbsp;Azize Karahan","doi":"10.1016/j.trre.2025.100961","DOIUrl":"10.1016/j.trre.2025.100961","url":null,"abstract":"<div><h3>Objective</h3><div>This study synthesizes qualitative research on the lived experiences of individuals awaiting kidney transplantation, with particular attention to their emotional, psychological, and social journeys during the waiting period.</div></div><div><h3>Methods</h3><div>A meta-ethnographic approach was employed, guided by Noblit and Hare's seven-phase framework. Systematic searches were conducted across six databases—PubMed (MEDLINE), Scopus, Web of Science, ScienceDirect, Wiley, and Ovid—resulting in 5452 records. After applying predefined eligibility criteria, eight qualitative studies published between 2015 and 2025 were included. First-order constructs (participants' accounts) and second-order constructs (researchers' interpretations) were integrated to generate third-order interpretive themes.</div></div><div><h3>Results</h3><div>Six overarching themes were identified: (1) navigating uncertainty, (2) sustaining hope and anticipation, (3) psychological strain and emotional weight, (4) readiness and coping resources, (5) support systems and communication, and (6) identity transformation and personal growth. These themes emphasize the complexity of the experience of waiting for a transplant, which is characterized by temporal ambiguity, emotional vulnerability, and existential reflection. Support from peers and healthcare professionals, as well as adaptive coping strategies, played a pivotal role in fostering psychological resilience.</div></div><div><h3>Conclusion</h3><div>Waiting for a kidney transplant profoundly reshapes patients' perceptions of self, time, and well-being. Insights from this synthesis can guide the design of targeted psychosocial interventions and patient-centered support programs. These findings hold relevance for nurses, transplant coordinators, and mental health practitioners involved in caring for this population.</div></div>","PeriodicalId":48973,"journal":{"name":"Transplantation Reviews","volume":"39 4","pages":"Article 100961"},"PeriodicalIF":3.6,"publicationDate":"2025-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144890846","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Adaptive immune response and evasion strategies of BK virus","authors":"Deema Ibrahim Fallatah ,&nbsp;Steve Christmas ,&nbsp;Abdulkarim Binshaya","doi":"10.1016/j.trre.2025.100959","DOIUrl":"10.1016/j.trre.2025.100959","url":null,"abstract":"<div><div>BKV presents a considerable challenge, particularly in immunocompromised individuals such as kidney transplant recipients. This review explores the adaptive immune responses to BKV, focusing on both humoral and cellular immunity. While BKV-specific antibodies contribute to viral neutralization, their protective role is limited due to viral immune evasion strategies and serotype variations. Cellular immunity, especially BKV-specific T-cell responses, plays a crucial role in con-trolling viral replication and preventing nephropathy. However, BKV employs several immune evasion tactics, including antigenic variation, latency, and modulation of T-cell responses. The absence of standardized serological assays further complicates diagnosis and immune monitoring. Future research should focus on improving diagnostic tools, identifying biomarkers, and developing targeted immunotherapies. Understanding the mechanisms of BKV immune evasion and latency will be essential for improving clinical outcomes in high-risk populations.</div></div>","PeriodicalId":48973,"journal":{"name":"Transplantation Reviews","volume":"39 4","pages":"Article 100959"},"PeriodicalIF":3.6,"publicationDate":"2025-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144860734","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The impact of standard- versus reduced-dose tacrolimus exposure on clinical outcomes in adult kidney transplant recipients: A systematic review and meta-analysis","authors":"Suwasin Udomkarnjananun ,&nbsp;Mohamed Soliman ,&nbsp;Sangil Min ,&nbsp;Ha Phan Hai An ,&nbsp;Chih-Yuan Lee ,&nbsp;Yongji Lu ,&nbsp;Teun van Gelder","doi":"10.1016/j.trre.2025.100958","DOIUrl":"10.1016/j.trre.2025.100958","url":null,"abstract":"<div><div>Concerns around calcineurin inhibitor–induced nephrotoxicity after kidney transplantation have led to dose-reduction practices. However, “reduced dose” remains poorly defined, and evidence comparing outcomes for standard- versus reduced-dose tacrolimus trough concentration (C₀) above 5 ng/mL is limited. We searched multiple electronic databases (Jan 1, 2000-June 30, 2024) for randomized controlled or observational studies that reported clinical outcomes (acute rejection, nephrotoxicity, graft survival, patient survival, and estimated glomerular filtration rate) directly against tacrolimus C₀ as an independent clinical variable in adult kidney transplant recipients who received tacrolimus. Ten publications were included. No eligible study of tacrolimus with mammalian target of rapamycin inhibitors was identified, so results focused on patients treated with tacrolimus plus mycophenolic acid. Four randomized controlled trials with similar immunosuppression regimens were included in the meta-analysis to compare the impact of standard- versus reduced-dose tacrolimus exposure (per study definition) on C₀ and clinical outcomes. Standard-dose tacrolimus exposure was associated with significantly lower acute rejection rates versus reduced-dose exposure (odds ratio, 0.4 [95 % confidence interval: 0.17, 0.95]; <em>P</em> = 0.037). There were no significant differences between groups in graft loss or patient survival. An overlap in drug concentrations between standard- and reduced-dose tacrolimus C₀ suggests that reduced-dose tacrolimus regimens can often result in an exposure that falls within the standard range (i.e., 5–10 ng/mL). Clinicians should consider the precise tacrolimus dose ranges reported in publications and optimize tacrolimus concentration levels for individual patients, potentially contradicting some recommendations for calcineurin inhibitor minimization.</div></div>","PeriodicalId":48973,"journal":{"name":"Transplantation Reviews","volume":"39 4","pages":"Article 100958"},"PeriodicalIF":3.6,"publicationDate":"2025-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144863468","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Renal resistance during hypothermic machine perfusion: A scoping review of variability and determinants, with a meta-analysis of predictive value for transplant outcomes","authors":"Liliana Fonseca Buitrago ,&nbsp;Laurence Verstraeten ,&nbsp;Steffen Fieuws ,&nbsp;Ina Jochmans","doi":"10.1016/j.trre.2025.100956","DOIUrl":"10.1016/j.trre.2025.100956","url":null,"abstract":"<div><h3>Background</h3><div>Renal resistance (RR) measured during hypothermic machine perfusion (HMP) is used to assess donor kidney quality and guide transplantation decisions. However, its clinical reliability and relationship with donor factors remain unclear.</div></div><div><h3>Methods</h3><div>This scoping review and meta-analysis evaluate the variability, determinants, and predictive value of RR during HMP. A systematic search of PubMed, Embase, Web of Science, and Cochrane Library (July 2024) identified 49 primary studies reporting RR in perfused human kidneys. The risk of bias was assessed using the ROBINS-I tool. Meta-analyses for the predictive value of RR were performed when ≥3 studies reported univariable associations for the same time point and outcome.</div></div><div><h3>Results</h3><div>Most studies had moderate to serious risk of bias. RR typically declined rapidly, stabilizing within 5 h (range: 0.30–3.50 to 0.17–1.50 mmHg/mL/min), but patterns varied widely. Determinants included histology, donor characteristics, and perfusion additives, though evidence was inconsistent. A meta-analysis showed terminal RR was significantly associated with delayed graft function (odds ratio 2.49, 95 % CI 1.49–4.18, I² = 58 %). While several studies proposed RR-thresholds, none were consistently validated, and heterogeneity in measurement timings and device settings limits comparability.</div></div><div><h3>Conclusion</h3><div>RR shows potential as a functional assessment parameter during HMP but is influenced by multiple technical and biological factors. Current evidence does not support the use of isolated RR-thresholds for organ acceptance. Standardized HMP protocols, trajectory modeling, and prospective studies are needed to clarify RR's role in clinical decision-making.</div></div>","PeriodicalId":48973,"journal":{"name":"Transplantation Reviews","volume":"39 4","pages":"Article 100956"},"PeriodicalIF":3.6,"publicationDate":"2025-07-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144670291","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Graft-versus-host disease after liver transplantation: A global review of pathogenesis, diagnosis, and treatment strategies","authors":"Ayato Obana ,&nbsp;Miho Akabane ,&nbsp;Khalid Mumtaz ,&nbsp;Lauren Von Stein ,&nbsp;Johanna Papanikolla ,&nbsp;Nicole Gray ,&nbsp;Lindsay Sobotka ,&nbsp;Sylvester Black","doi":"10.1016/j.trre.2025.100942","DOIUrl":"10.1016/j.trre.2025.100942","url":null,"abstract":"<div><div>Graft-versus-host disease (GVHD) following liver transplantation (LT) (GVHD-LT) is a rare but highly lethal complication, occurring in 0.1–2 % of recipients with mortality rates exceeding 75 %. GVHD-LT develops when donor-derived lymphocytes transferred within the hepatic allograft recognize recipient tissues as foreign and mount an immune attack, primarily targeting the skin, gastrointestinal tract, and bone marrow while characteristically sparing the donor liver graft itself. This comprehensive review synthesizes current knowledge of GVHD-LT pathogenesis, clinical manifestations, diagnostic approaches, and therapeutic strategies based on systematic literature analysis of cases reported from 1988 to 2025. Clinical presentation typically occurs 2–12 weeks post-transplant with the classic triad of fever, maculopapular rash, profuse diarrhea, and progressive pancytopenia. Diagnosis relies on tissue biopsy demonstrating characteristic histopathological changes combined with molecular chimerism analysis confirming donor lymphocyte persistence. Risk factors include recipient age &gt; 50 years, hepatocellular carcinoma as underlying disease, and specific donor-recipient immunologic mismatches. Management remains challenging due to the delicate balance required between intensifying immunosuppression to control donor lymphocyte activity while preventing overwhelming infection. Conventional high-dose corticosteroids yield poor outcomes, with emerging therapies including JAK inhibitors, extracorporeal photopheresis, and targeted cytokine blockade showing promise in steroid-refractory cases. The hyperinflammatory state frequently overlaps with hemophagocytic lymphohistiocytosis, requiring specialized therapeutic approaches. Despite therapeutic advances, prognosis remains poor, with sepsis from opportunistic infections representing the leading cause of death. Future directions emphasize the urgent need for risk stratification models, preventive strategies, and multi-institutional collaborative trials to improve outcomes for this devastating post-transplant complication.</div></div>","PeriodicalId":48973,"journal":{"name":"Transplantation Reviews","volume":"39 4","pages":"Article 100942"},"PeriodicalIF":3.6,"publicationDate":"2025-07-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144654386","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Emerging strategies in the transplantation of HCV-infected pancreases to uninfected recipients: A narrative review","authors":"Adam J. Bush ,&nbsp;Robyn A.E. Gould ,&nbsp;Benjamin C. Storey ,&nbsp;Matthew J. Bottomley","doi":"10.1016/j.trre.2025.100941","DOIUrl":"10.1016/j.trre.2025.100941","url":null,"abstract":"<div><div>The scarcity of suitable candidates for solid organ transplantation (SOT) represents a major barrier to the reduction of waiting lists. The introduction of direct-acting antiviral (DAA) therapeutics eliminates many of the risks associated with the transplantation of Hepatitis C Virus (HCV)-infected donor organs (D+) to uninfected recipients (R-) and may facilitate access to a substantial organ pool, previously considered unacceptably high risk. The extent of clinical investigation into the safety and feasibility of HCV D+/R- SOT varies between allograft types.</div><div>Here, we review the current state of pancreatic HCV D+/R-transplant research. Studies are limited to small cohorts who received pancreas allografts from HCV-viraemic donors alongside a regimen of DAA therapy. As of 2025, seven studies investigated a total of 22 patients, using prophylactic or reactive treatment regimens. Outcomes have been positive, with universal viral eradication, favourable allograft function, and minimal HCV-related complications. A favourable adverse event profile is reported, mirroring studies in other transplanted organs.</div><div>With the aim to increase clinical use of pancreatic HCV D+/R- SOT, further investigation in the field is necessary to validate these preliminary data. Larger studies are essential to evaluate long-term sequelae and optimise treatment protocols to subsequently establish a standard of care.</div></div>","PeriodicalId":48973,"journal":{"name":"Transplantation Reviews","volume":"39 4","pages":"Article 100941"},"PeriodicalIF":3.6,"publicationDate":"2025-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144587695","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}